- Conditions
- Familial Hypercholesterolaemia
- Interventions
- Alert-based computerized decision support
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
- Interventions
- Physician counseling for health behavior change
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 6
- States / cities
- Corpus Christi, Texas • Harlingen, Texas • Laredo, Texas + 2 more
- Conditions
- Severe Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Hypercholesterolemia
- Interventions
- Not listed
- Lead sponsor
- The Familial Hypercholesterolemia Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Biological · Procedure
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Interventions
- Volanesorsen
- Drug
- Lead sponsor
- Akcea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 8
- States / cities
- Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
- Interventions
- mipomersen sodium
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Cascade screening
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
- Interventions
- Plozasiran
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 15 Years and older
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 26
- States / cities
- Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- atorvastatin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 6 Years to 15 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more
- Conditions
- Hypercholesterolemia, Familial, Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 14
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Lutz, Florida + 11 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- lerodalcibep, evolocumab
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Cincinnati, Ohio
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Cascade Screening
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypercholesterolemia, Hyperlipidemia, Familial Combined
- Interventions
- colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 10
- States / cities
- Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- 300mg Gemcabene, 600mg Gemcabene
- Drug
- Lead sponsor
- Elif Oral
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
- Drug
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
- Conditions
- Hyperlipidemias
- Interventions
- No Intervention
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
- Interventions
- Direct contact of family members for cascade screening of relevant variants
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Hypertriglyceridemia, Familial Chylomicronemia Syndrome
- Interventions
- RN0361
- Drug
- Lead sponsor
- Ikaria Bioscience Pty Ltd
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
- Interventions
- mipomersen, Placebo
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Cincinnati, Ohio
- Conditions
- Hypercholesterolaemia
- Interventions
- alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Interventions
- Inclisiran, Evolocumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more